1962928-26-2
1962928-26-2 structure
- Name: BGC 20-1531 hydrochloride
- Chemical Name: 4-{[4-(5-Methoxy-2-pyridinyl)phenoxy]methyl}-5-methyl-N-[(2-methylphenyl)sulfonyl]-2-furamide hydrochloride (1:1)
- CAS Number: 1962928-26-2
- Molecular Formula: C26H25ClN2O6S
- Molecular Weight: 529.005
- Catalog: Signaling Pathways GPCR/G Protein Prostaglandin Receptor
- Create Date: 2020-01-20 18:59:56
- Modify Date: 2025-08-24 20:28:19
-
BGC20-1531 (PGN-1531, AP 1531) is a potent, selective prostanoid EP receptor EP antagonist, exhibits high affinity at recombinant human EP4 receptors expressed in cell lines (pKB=7.6) and native EP4 receptors in human cerebral and meningeal artery (pKB=7.6-7.8); shows no appreciable affinity at a wide range of other receptors (including other prostanoid receptors), channels, transporters and enzymes (pKi < 5); competitively antagonizes PGE(2)-induced vasodilatation of human middle cerebral (pK(B) 7.8) and meningeal (pK(B) 7.6) arteries in vitro, and PGE(2)-induced increase in canine carotid blood flow in vivo. Migraine Phase 2 Discontinued
| Name | 4-{[4-(5-Methoxy-2-pyridinyl)phenoxy]methyl}-5-methyl-N-[(2-methylphenyl)sulfonyl]-2-furamide hydrochloride (1:1) |
|---|---|
| Synonyms |
2-Furancarboxamide, 4-[[4-(5-methoxy-2-pyridinyl)phenoxy]methyl]-5-methyl-N-[(2-methylphenyl)sulfonyl]-, hydrochloride (1:1)
4-{[4-(5-Methoxy-2-pyridinyl)phenoxy]methyl}-5-methyl-N-[(2-methylphenyl)sulfonyl]-2-furamide hydrochloride (1:1) |
| Description | BGC20-1531 (PGN-1531, AP 1531) is a potent, selective prostanoid EP receptor EP antagonist, exhibits high affinity at recombinant human EP4 receptors expressed in cell lines (pKB=7.6) and native EP4 receptors in human cerebral and meningeal artery (pKB=7.6-7.8); shows no appreciable affinity at a wide range of other receptors (including other prostanoid receptors), channels, transporters and enzymes (pKi < 5); competitively antagonizes PGE(2)-induced vasodilatation of human middle cerebral (pK(B) 7.8) and meningeal (pK(B) 7.6) arteries in vitro, and PGE(2)-induced increase in canine carotid blood flow in vivo. Migraine Phase 2 Discontinued |
|---|---|
| References | References 1. Maubach KA, et al. Br J Pharmacol. 2009 Jan;156(2):316-27. 2. Antonova M, et al. J Headache Pain. 2011 Oct;12(5):551-9. View Related Products by Target Prostaglandin Receptor Migraine |
| Molecular Formula | C26H25ClN2O6S |
|---|---|
| Molecular Weight | 529.005 |
| Exact Mass | 528.112183 |